deaths (OS)progression or deaths (PFS)RFS/DFS

endometrial cancer endometrial cancer

versus paclitaxel
pembrolizumab plus lenvatinib vs. paclitaxel 1 0.62 [0.51; 0.75], 1 RCT, I2=0%
unassessable degree of certainty
0.56 [0.47; 0.66], 1 RCT, I2=0%
unassessable degree of certainty
-